Medical & Regulatory Affairs
In November 2018, a cancer patient received treatment for their disease with InnoMedica's chemotherapy for the first time – a great moment in the history of InnoMedica. Together with the Swiss Working Group for Clinical Cancer Research (SAKK), the umbrella organization for Swiss oncologists, InnoMedica is conducting a phase I clinical study in Swiss hospitals. In consultation with Swissmedic and the European Medicines Agency (EMA), the team was working on the next steps for approval of the cancer drug and the start of a clinical trial of the product against neurodegenerative diseases.
The four-person team in the Medical Affairs division is responsible for planning and supervising the ongoing and forthcoming clinical trials which are conducted in collaboration with partners (e.g. SAKK) or directly with the hospitals. In addition, the team is supervising the exchange with the medical profession and the authorities.
Noëmi Müller (lawyer) together with her team and in cooperation with the Medical Affairs Team, ensure all documents for submission are in compliance with the regulatory provisions, and present the approval dossiers with the necessary documents for the submission.
Dr. Pascal Baumgartner – PhD in Pharmaceutical Sciences, University of Basel; previously: Pharmacist at 24 Stunden Apotheke Basel
Dr. Petra Gottier – PhD in Biochemistry and Molecular Biology, University of Bern; previously: Postdoctoral Researcher and Lab Manager at the Institute of Biochemistry and Molecular Medicine, University of Bern
Lisa Halbherr – Master of Science in Neuropsychology, University of Zurich & Beth Israel Deaconess Medical Center, Boston und International MBA, IE Instituto de Empresa Madrid; previously: Project Manager Market Research
Dr. Stefanie Lerch – PhD in Pharmaceutical Sciences, University of Bern and ETH Zurich; previously: Head Neuroclinical Trial Unit, Inselspital Bern
RA Noëmi Müller – Master of Law, University of Lausanne and University of Bern; Admitted to the bar in the Canton of Bern; previously: Legal Associate Tax Administration of the Canton of Bern
Petra Polakova – Master of Science in Biomedical Sciences, University of Bern; previously: Clinical Research Associate at Swiss Group for Clinical Cancer Research (SAKK)
Dr. Andreas Schittny – PhD in Pharmaceutical Sciences, University of Basel; previously: Postdoc in Pharmaceutical Technology at the Department of Pharmaceutical Sciences, University of Basel and Subject Manager Quality and Patient Safety at H+ Die Spitäler der Schweiz
Prof. Dr. med. Beat Thürlimann – Senior Consultant at the Breast Center of the Cantonal Hospital St. Gallen and former President of the Swiss Group for Clinical Cancer Research (SAKK)